特应性皮炎的现实负担：巴西、墨西哥和阿根廷的MEASURE-AD结果。

IF 2.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia Pub Date : 2025-05-01 DOI:10.1016/j.abd.2024.05.011

Catalina Rincón Pérez , Valeria Aoki , Roberta F. Criado , Martti Antila , Maria Valeria Angles , Tania Ferreira Cestari , Delfina Guadalupe Villanueva Quintero , Gabriel Magariños , Carla Castro , Adriana López Tello-Santillán , Magda Weber , Daniel Lorenzini , Caio Cesar Silva de Castro , Jorge Maspero , Linda García-Hidalgo , Limei Zhou , Shereen Hammad , Lucila de Campos , Tatiane Cristina Rodrigues , Carolina Arzelán , Paula C. Luna

{"title":"特应性皮炎的现实负担：巴西、墨西哥和阿根廷的MEASURE-AD结果。","authors":"Catalina Rincón Pérez , Valeria Aoki , Roberta F. Criado , Martti Antila , Maria Valeria Angles , Tania Ferreira Cestari , Delfina Guadalupe Villanueva Quintero , Gabriel Magariños , Carla Castro , Adriana López Tello-Santillán , Magda Weber , Daniel Lorenzini , Caio Cesar Silva de Castro , Jorge Maspero , Linda García-Hidalgo , Limei Zhou , Shereen Hammad , Lucila de Campos , Tatiane Cristina Rodrigues , Carolina Arzelán , Paula C. Luna","doi":"10.1016/j.abd.2024.05.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Atopic dermatitis (AD) burden increases with disease severity.</div></div><div><h3>Objective</h3><div>Characterize the real-world burden of AD in Brazil, Mexico, and Argentina.</div></div><div><h3>Methods</h3><div>MEASURE-AD enrolled patients (≥12-years old) with moderate to severe AD receiving or candidates for systemic therapy between December 2019-December 2020. Patient characteristics, treatments, and outcomes were recorded during one office visit. Primary outcome measures included worst itch/past 24hours (Worst Pruritus Numerical Rating Scale [WP-NRS]), quality of life (QoL, Dermatology Life Quality Index [DLQI] and Children's DLQI [CDLQI]).</div></div><div><h3>Results</h3><div>Of 180 patients (adults, n=157; adolescents, n=23), 52.2% were male, the mean (SD) age was 33.8 (17.0) years, and all were receiving AD treatment (65.6% systemic therapy). Severe pruritus (WP-NRS ≥ 7) was reported by 54.4% (adults, 57.3%; adolescents, 34.8%). A very/extremely large effect on QoL (DLQI/CDLQI≥11) was reported among 50.0% of patients ≥ 16 years old and 42.9% of patients 12–15 years old. The mean Eczema Area Severity Index (EASI) was 17.0 (adults, 17.7; adolescents, 12.4); 3.9% of patients had clear skin (EASI 0) and 26.7% had severe AD (EASI 23–72). Over the previous 6 months, 0, 1–2, 3–4, 5–6, and > 6 flares were reported by 8.3%, 27.2%, 31.1%, 11.7%, and 15.6% of patients, respectively. On average, flares lasted 15.2 days (adults, 15.9 days; adolescents, 11.1 days).</div></div><div><h3>Study limitations</h3><div>Patient self-reported information and recall during one office visit.</div></div><div><h3>Conclusions</h3><div>Despite treatment, disease severity and impact on QoL were high, suggesting that AD is not adequately controlled in all patients, highlighting a considerable unmet need for effective treatments to reduce AD burden.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 3","pages":"Pages 470-486"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina\",\"authors\":\"Catalina Rincón Pérez , Valeria Aoki , Roberta F. Criado , Martti Antila , Maria Valeria Angles , Tania Ferreira Cestari , Delfina Guadalupe Villanueva Quintero , Gabriel Magariños , Carla Castro , Adriana López Tello-Santillán , Magda Weber , Daniel Lorenzini , Caio Cesar Silva de Castro , Jorge Maspero , Linda García-Hidalgo , Limei Zhou , Shereen Hammad , Lucila de Campos , Tatiane Cristina Rodrigues , Carolina Arzelán , Paula C. Luna\",\"doi\":\"10.1016/j.abd.2024.05.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Atopic dermatitis (AD) burden increases with disease severity.</div></div><div><h3>Objective</h3><div>Characterize the real-world burden of AD in Brazil, Mexico, and Argentina.</div></div><div><h3>Methods</h3><div>MEASURE-AD enrolled patients (≥12-years old) with moderate to severe AD receiving or candidates for systemic therapy between December 2019-December 2020. Patient characteristics, treatments, and outcomes were recorded during one office visit. Primary outcome measures included worst itch/past 24hours (Worst Pruritus Numerical Rating Scale [WP-NRS]), quality of life (QoL, Dermatology Life Quality Index [DLQI] and Children's DLQI [CDLQI]).</div></div><div><h3>Results</h3><div>Of 180 patients (adults, n=157; adolescents, n=23), 52.2% were male, the mean (SD) age was 33.8 (17.0) years, and all were receiving AD treatment (65.6% systemic therapy). Severe pruritus (WP-NRS ≥ 7) was reported by 54.4% (adults, 57.3%; adolescents, 34.8%). A very/extremely large effect on QoL (DLQI/CDLQI≥11) was reported among 50.0% of patients ≥ 16 years old and 42.9% of patients 12–15 years old. The mean Eczema Area Severity Index (EASI) was 17.0 (adults, 17.7; adolescents, 12.4); 3.9% of patients had clear skin (EASI 0) and 26.7% had severe AD (EASI 23–72). Over the previous 6 months, 0, 1–2, 3–4, 5–6, and > 6 flares were reported by 8.3%, 27.2%, 31.1%, 11.7%, and 15.6% of patients, respectively. On average, flares lasted 15.2 days (adults, 15.9 days; adolescents, 11.1 days).</div></div><div><h3>Study limitations</h3><div>Patient self-reported information and recall during one office visit.</div></div><div><h3>Conclusions</h3><div>Despite treatment, disease severity and impact on QoL were high, suggesting that AD is not adequately controlled in all patients, highlighting a considerable unmet need for effective treatments to reduce AD burden.</div></div>\",\"PeriodicalId\":7787,\"journal\":{\"name\":\"Anais brasileiros de dermatologia\",\"volume\":\"100 3\",\"pages\":\"Pages 470-486\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anais brasileiros de dermatologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S036505962500025X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anais brasileiros de dermatologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S036505962500025X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：特应性皮炎（AD）负担随着疾病严重程度的增加而增加。目的：描述巴西、墨西哥和阿根廷阿尔茨海默病的现实负担。方法：MEASURE-AD纳入2019年12月至2020年12月期间接受或拟接受全身治疗的中重度AD患者（≥12岁）。在一次办公室访问期间记录患者特征，治疗和结果。主要结局指标包括最严重瘙痒/过去24小时（最严重瘙痒数值评定量表[WP-NRS]）、生活质量（QoL）、皮肤病生活质量指数[DLQI]和儿童DLQI [CDLQI])。结果：180例患者(成人，n=157；青少年，n=23)， 52.2%为男性，平均（SD）年龄为33.8（17.0）岁，均接受AD治疗（65.6%为全身治疗）。重度瘙痒（WP-NRS≥7）者占54.4%(成人57.3%；青少年,34.8%)。50.0%≥16岁的患者和42.9%的12-15岁的患者对生活质量（DLQI/CDLQI≥11）有非常/极大的影响。平均湿疹面积严重指数（EASI）为17.0(成人17.7；青少年,12.4);3.9%的患者皮肤清晰（EASI 0）， 26.7%的患者患有重度AD （EASI 23-72）。在过去的6个月中，分别有8.3%、27.2%、31.1%、11.7%和15.6%的患者报告了0、1-2、3-4、5-6和bb0 -6的耀斑。平均持续15.2天(成人15.9天；青少年，11.1天)。研究局限性：患者在一次办公室访问中自我报告的信息和回忆。结论：尽管进行了治疗，但疾病的严重程度和对生活质量的影响都很高，表明AD在所有患者中并未得到充分控制，这表明对有效治疗减轻AD负担的需求仍未得到充分满足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina

Background

Atopic dermatitis (AD) burden increases with disease severity.

Objective

Characterize the real-world burden of AD in Brazil, Mexico, and Argentina.

Methods

MEASURE-AD enrolled patients (≥12-years old) with moderate to severe AD receiving or candidates for systemic therapy between December 2019-December 2020. Patient characteristics, treatments, and outcomes were recorded during one office visit. Primary outcome measures included worst itch/past 24 hours (Worst Pruritus Numerical Rating Scale [WP-NRS]), quality of life (QoL, Dermatology Life Quality Index [DLQI] and Children's DLQI [CDLQI]).

Results

Of 180 patients (adults, n = 157; adolescents, n = 23), 52.2% were male, the mean (SD) age was 33.8 (17.0) years, and all were receiving AD treatment (65.6% systemic therapy). Severe pruritus (WP-NRS ≥ 7) was reported by 54.4% (adults, 57.3%; adolescents, 34.8%). A very/extremely large effect on QoL (DLQI/CDLQI ≥ 11) was reported among 50.0% of patients ≥ 16 years old and 42.9% of patients 12–15 years old. The mean Eczema Area Severity Index (EASI) was 17.0 (adults, 17.7; adolescents, 12.4); 3.9% of patients had clear skin (EASI 0) and 26.7% had severe AD (EASI 23–72). Over the previous 6 months, 0, 1–2, 3–4, 5–6, and > 6 flares were reported by 8.3%, 27.2%, 31.1%, 11.7%, and 15.6% of patients, respectively. On average, flares lasted 15.2 days (adults, 15.9 days; adolescents, 11.1 days).

Study limitations

Patient self-reported information and recall during one office visit.

Conclusions

Despite treatment, disease severity and impact on QoL were high, suggesting that AD is not adequately controlled in all patients, highlighting a considerable unmet need for effective treatments to reduce AD burden.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anais brasileiros de dermatologia DERMATOLOGY-

CiteScore

2.40

自引率

0.00%

发文量

184

审稿时长

32 days

期刊介绍： The journal is published bimonthly and is devoted to the dissemination of original, unpublished technical-scientific study, resulting from research or reviews of dermatological topics and related matters. Exchanges with other publications may be accepted.